Hematology & Oncology

Research output

Research output per year 1956 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

• 1861 Article
• 259 Review article
• 101 Comment/debate
• 72 Letter
• 122 More
  • 63 Editorial
  • 37 Chapter
  • 18 Short survey
  • 2 Book
  • 2 Conference contribution

Research output per year

Research output per year

Search results

• 2024

  Ahemolytic PNH (white cell PNH): Clinical features and implications of a distinct phenotype of paroxysmal nocturnal haemoglobinuria

  Tombul, Z., Bahaj, W., Ozturk, M., Patel, B., Toprak, A., Ibrahim, I. F., Chen, W., Fuda, F., Ogbue, O. D., Gurnari, C., Parker, C., Young, N. S., Maciejewski, J. P., Duran, M. & Bat, T., 2024, (Accepted/In press) In: British Journal of Haematology.

  Research output: Contribution to journal › Letter › peer-review

• Anticancer benzoxaboroles block pre-mRNA processing by directly inhibiting CPSF3

  Tao, Y., Budhipramono, A., Huang, J., Fang, M., Xie, S., Kim, J., Khivansara, V., Dominski, Z., Tong, L., De Brabander, J. K. & Nijhawan, D., Jan 18 2024, In: Cell Chemical Biology. 31, 1, p. 139-149.e14

  Research output: Contribution to journal › Article › peer-review

  • Benzoxaborole 100%
  • mRNA Cleavage and Polyadenylation Factors 98%
  • RNA Precursors 65%
  • Cleavage 39%
  • Block Like Crystal 38%

• A Tale of Two Hospitals: Effect of Access to Care Through a Safety Net Hospital on Adjuvant Therapy, Imaging Compliance and 5-Year Survival Rates Compared to the University Hospital Served by the Same Breast Cancer Clinical Teams

  Mootz, A. R., Ozcan, B. B., Polat, D. S., Acevedo, Z., Xi, Y., Unni, N., Nwachukwu, C. & Dogan, B. E., 2024, (Accepted/In press) In: Academic radiology.

  Research output: Contribution to journal › Article › peer-review

  • Safety-net Providers 100%
  • Compliance 59%
  • University Hospitals 51%
  • Survival Rate 49%
  • Breast Neoplasms 42%

• A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small cell lung cancer

  Eglenen-Polat, B., Kowash, R. R., Huang, H. C., Siteni, S., Zhu, M., Chen, K., Bender, M. E., Mender, I., Stastny, V., Drapkin, B. J., Raj, P., Minna, J. D., Xu, L., Shay, J. W. & Akbay, E. A., Dec 2024, In: Nature communications. 15, 1, 672.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • alpha-2'-deoxythioguanosine 100%
  • telomeres 89%
  • Nucleoside Analogue 64%
  • immunity 61%
  • Small Cell Lung Carcinoma 58%

• Author Correction: Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial (Nature Medicine, (2023), 29, 3, (615-622), 10.1038/s41591-022-02141-2)

  Mellinghoff, I. K., Lu, M., Wen, P. Y., Taylor, J. W., Maher, E. A., Arrillaga-Romany, I., Peters, K. B., Ellingson, B. M., Rosenblum, M. K., Chun, S., Le, K., Tassinari, A., Choe, S., Toubouti, Y., Schoenfeld, S., Pandya, S. S., Hassan, I., Steelman, L., Clarke, J. L. & Cloughesy, T. F., Jan 2024, In: Nature medicine. 30, 1, p. 302 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • ivosidenib 100%
  • Glioma 46%
  • Medicine 36%

• Author Correction: Molecular patterns identify distinct subclasses of myeloid neoplasia(Nature Communications, 10.1038/s41467-023-38515-4)

  Kewan, T., Durmaz, A., Bahaj, W., Gurnari, C., Terkawi, L., Awada, H., Ogbue, O. D., Ahmed, R., Pagliuca, S., Awada, H., Kubota, Y., Mori, M., Ponvilawan, B., Al-Share, B., Patel, B. J., Carraway, H. E., Scott, J., Balasubramanian, S. K., Bat, T., Madanat, Y., & 4 othersSekeres, M. A., Haferlach, T., Visconte, V. & Maciejewski, J. P., Dec 2024, In: Nature communications. 15, 1, 1184.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • Names 100%
  • Communication 95%
  • communication 86%
  • Neoplasms 34%

• Bortezomib in relapsed/refractory immune thrombotic thrombocytopenic purpura: A single-centre retrospective cohort and systematic literature review

  Lee, N. C. J., Yates, S., Rambally, S., Sarode, R., Ibrahim, I. F., Shen, Y. M., Hofmann, S. L. & Bavli, N. R., Feb 2024, In: British Journal of Haematology. 204, 2, p. 638-643 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Thrombotic Thrombocytopenic Purpura 100%
  • Bortezomib 91%
  • Idiopathic Thrombocytopenic Purpura 88%
  • Systematic Reviews 54%
  • Plasma Exchange 45%
  1 Scopus citations

• Comparative study of dexamethasone premedication regimens with docetaxel chemotherapy in early HER-2 positive breast cancer: A safety net hospital experience

  Hager, A., Kondle, S., Agarwal, A., Chintapenta, M., Horadam, R., Sadeghi, N. & Syed, S. K., 2024, (Accepted/In press) In: Journal of Oncology Pharmacy Practice.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Safety-net Providers 100%
  • Premedication 80%
  • Docetaxel 73%
  • Dexamethasone 60%
  • Breast Neoplasms 42%

• Contemporary Trends in Reviewing Test Results Through the Electronic Patient Portal among Patients with Cancer

  Bhalla, S., Prasad, T., Xie, D. & Gerber, D. E., Jan 18 2024, In: JAMA Oncology. 10, 1, p. 139-140 2 p.

  Research output: Contribution to journal › Article › peer-review

• Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522

  Pusztai, L., Denkert, C., O'Shaughnessy, J., Cortes, J., Dent, R., McArthur, H., Kümmel, S., Bergh, J., Park, Y. H., Hui, R., Harbeck, N., Takahashi, M., Untch, M., Fasching, P. A., Cardoso, F., Zhu, Y., Pan, W., Tryfonidis, K. & Schmid, P., 2024, (Accepted/In press) In: Annals of Oncology.

  Research output: Contribution to journal › Article › peer-review

  • pembrolizumab 100%
  • Triple Negative Breast Neoplasms 85%
  • Residual Neoplasm 75%
  • Progression-Free Survival 64%
  • Placebos 12%

• Feasibility of institution-agnostic, EHR-integrated regional clinical trial matching

  Shriver, S. P., Arafat, W., Potteiger, C., Butler, D. L., Beg, M. S., Hullings, M., Semy, S., Lister, Z., Khosama, L., Armstrong, S., Hadley, D., Pappa, J. & Fleury, M. E., Jan 1 2024, In: Cancer. 130, 1, p. 60-67 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Clinical Trials 100%
  • Electronic Health Records 31%
  • Patient Participation 17%
  • Neoplasms 14%
  • Drug Development 14%
  2 Scopus citations

• Genomic heterogeneity within B/T mixed phenotype acute leukemia in a context of an immunophenotype

  Zheng, R., Fuda, F., Gagan, J. R., Weinberg, O. K., Koduru, P., Cantu, M., Ludwig, K., Truscott, J. M., Collins, R., Chung, S., Madanat, Y. F. & Chen, W., Jan 2024, In: Leukemia Research Reports. 21, 100410.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Leukemia 100%
  • Phenotype 73%
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 53%
  • Genetic Association Studies 21%
  • Cytogenetics 20%

• Induced degradation of lineage-specific oncoproteins drives the therapeutic vulnerability of small cell lung cancer to PARP inhibitors

  Kim, C., Wang, X. D., Liu, Z., Hao, J., Wang, S., Li, P., Zi, Z., Ding, Q., Jang, S., Kim, J., Luo, Y., Huffman, K. E., Choudhuri, S. P., del Rio, S., Cai, L., Liang, H., Drapkin, B. J., Minna, J. D. & Yu, Y., Jan 2024, In: Science Advances. 10, 3

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Poly(ADP-ribose) Polymerase Inhibitors 100%
  • Oncogene Proteins 84%
  • Small Cell Lung Carcinoma 83%
  • Proteomics 15%
  • Therapeutics 12%

• Intensifying supportive care is associated with improved survival in gastric cancer patients with malignant ascites

  Karalis, J. D., Ju, M. R., Feig, R., Estrella, R., Pettigrew, M. F., Alterio, R. E., Abreu, A. A., Farah, E., Sawas, T., Sanford, N. N., Sanjeevaiah, A., Hammer, S. T. G., Porembka, M. R. & Wang, S. C., Mar 15 2024, In: Journal of Surgical Oncology. 129, 4, p. 718-727 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Ascites 100%
  • Stomach Neoplasms 87%
  • Survival 56%
  • Inpatients 20%
  • Drug Therapy 14%

• Kinome-wide siRNA screen identifies a DCLK2-TBK1 oncogenic signaling axis in clear cell renal cell carcinoma

  Hu, L., Zhang, Y., Guo, L., Zhong, H., Xie, L., Zhou, J., Liao, C., Yao, H., Fang, J., Liu, H., Zhang, C., Zhang, H., Zhu, X., Luo, M., von Kriegsheim, A., Li, B., Luo, W., Zhang, X., Chen, X., Mendell, J. T., & 5 othersXu, L., Kapur, P., Baldwin, A. S., Brugarolas, J. & Zhang, Q., Feb 15 2024, In: Molecular cell. 84, 4, p. 776-790.e5

  Research output: Contribution to journal › Article › peer-review

  • Renal Cell Carcinoma 100%
  • Small Interfering RNA 87%
  • Phosphotransferases 80%
  • Carcinogenesis 14%
  • Growth 9%

• Landscape and Saturation Analysis of Mutations Associated With Race in Cancer Genomes by Clinical Sequencing

  Muquith, M. & Hsiehchen, D., Mar 2024, In: Oncologist. 29, 3, p. 219-226 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Genome 100%
  • Mutation 82%
  • Mutation Rate 62%
  • Sample Size 52%
  • Neoplasms 47%

• LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development

  Huang, R., Liu, X., Kim, J., Deng, H., Deng, M., Gui, X., Chen, H., Wu, G., Xiong, W., Xie, J., Lewis, C., Homsi, J., Yang, X., Zhang, C., He, Y., Lou, Q., Smith, C., John, S., Zhang, N., An, Z., & 1 othersZhang, C. C., Mar 1 2024, In: Cancer Immunology Research. 12, 3, p. 350-362 13 p.

  Research output: Contribution to journal › Article › peer-review

  • Myeloid Cells 100%
  • Immunosuppressive Agents 81%
  • Leukocytes 77%
  • Neoplasms 31%
  • Galectin 4 19%
  1 Scopus citations

• Patient-Derived Models of Cancer in the NCI PDMC Consortium: Selection, Pitfalls, and Practical Recommendations

  Habowski, A. N., Budagavi, D. P., Scherer, S. D., Aurora, A. B., Caligiuri, G., Flynn, W. F., Langer, E. M., Brody, J. R., Sears, R. C., Foggetti, G., Arnal Estape, A., Nguyen, D. X., Politi, K. A., Shen, X., Hsu, D. S., Peehl, D. M., Kurhanewicz, J., Sriram, R., Suarez, M., Xiao, S., & 5 othersDu, Y., Li, X. N., Navone, N. M., Labanca, E. & Willey, C. D., Feb 2024, In: Cancers. 16, 3, 565.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Neoplasms 100%
  • National Cancer Institute (U.S.) 39%
  • Precision Medicine 37%
  • National Institutes of Health (U.S.) 35%
  • In Vitro Techniques 30%

• Physician Disruptive Behavior Compromising Safe Care Delivery

  Kumar, M., Das, D., Mulvey, T. M. & Sadeghi, N., Mar 1 2024, In: JCO Oncology Practice. 20, 3, p. 329-334 6 p.

  Research output: Contribution to journal › Article › peer-review

  • Problem Behavior 100%
  • physician 72%
  • Physicians 60%
  • management 45%

• Preoperative immune checkpoint inhibition and cryoablation in early-stage breast cancer

  Comen, E., Budhu, S., Elhanati, Y., Page, D., Rasalan-Ho, T., Ritter, E., Wong, P., Plitas, G., Patil, S., Brogi, E., Jochelson, M., Bryce, Y., Solomon, S. B., Norton, L., Merghoub, T. & McArthur, H. L., Feb 16 2024, In: iScience. 27, 2, 108880.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Cryosurgery 100%
  • Ipilimumab 64%
  • Breast Neoplasms 50%
  • Nivolumab 31%
  • T-Lymphocytes 28%

• Proteomics: A new dimension to decode small cell lung cancer

  Chen, H., Drapkin, B. J. & Minna, J. D., Jan 4 2024, In: Cell. 187, 1, p. 14-16 3 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  • Small Cell Lung Carcinoma 100%
  • Proteomics 82%
  • Dimension 67%
  • Neoplasms 19%

• Role of Neoadjuvant Therapy Prior to Curative Resection in Hepatocellular Carcinoma

  Whitham, Z. & Hsiehchen, D., Jan 2024, In: Surgical Oncology Clinics of North America. 33, 1, p. 87-97 11 p.

  Research output: Contribution to journal › Review article › peer-review

• The Joint Problem of Rheumatoid Arthritis and Lung Cancer

  Bermas, B. L. & Gerber, D. E., Feb 2024, In: Journal of Thoracic Oncology. 19, 2, p. 196-198 3 p.

  Research output: Contribution to journal › Editorial › peer-review

  Open Access

• The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trial

  Hsiehchen, D., Beg, M. S., Kainthla, R., Lohrey, J., Kazmi, S. M., Khosama, L., Maxwell, M. C., Kline, H., Katz, C., Hassan, A., Kubota, N., Siglinsky, E., Pillai, A. K., Youssoufian, H., Mockbee, C., Culm, K., Uhlik, M., Benjamin, L., Brekken, R. A., Ahn, C., & 4 othersSingal, A. G., Zhu, H., Hoshida, Y. & Yopp, A. C., Dec 2024, In: Nature communications. 15, 1, 2178.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • bavituximab 100%
  • pembrolizumab 66%
  • antibodies 56%
  • Phosphatidylserines 54%
  • cancer 44%

• Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers

  Muquith, M., Espinoza, M., Elliott, A., Xiu, J., Seeber, A., El-Deiry, W., Antonarakis, E. S., Graff, S. L., Hall, M. J., Borghaei, H., Hoon, D. S. B., Liu, S. V., Ma, P. C., McKay, R. R., Wise-Draper, T., Marshall, J., Sledge, G. W., Spetzler, D., Zhu, H. & Hsiehchen, D., 2024, (Accepted/In press) In: Nature Cancer.

  Research output: Contribution to journal › Article › peer-review

  • Microsatellite Repeats 100%
  • Tumor Burden 90%
  • Mutation 53%
  • Neoplasms 30%
  • Survival 22%

• Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations

  Pemmaraju, N., Madanat, Y. F., Rizzieri, D., Fazal, S., Rampal, R., Mannis, G., Wang, E. S., Foran, J. & Lane, A. A., 2024, (Accepted/In press) In: Leukemia and Lymphoma.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • tagraxofusp 100%
  • Dendritic Cells 43%
  • Neoplasms 15%
  • Therapeutics 7%
  • Practice Guidelines 6%
• 2023

  A case of hyperhemolysis syndrome in sickle cell disease and concomitant COVID-19

  Green, A., Jones, H., Nero, A., Ibrahim, I. F., Sarode, R., Scheid, L. M., Webb, C. B., Adkins, B. D. & Yates, S. G., Aug 2023, In: Transfusion and Apheresis Science. 62, 4, 103712.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Sickle Cell Anemia 100%
  • Erythrocyte Transfusion 67%
  • Hemoglobins 58%
  • SARS Virus 53%
  • Reticulocyte Count 24%

• Acetyl-Click Screening Platform Identifies Small-Molecule Inhibitors of Histone Acetyltransferase 1 (HAT1)

  Gaddameedi, J. D., Chou, T., Geller, B. S., Rangarajan, A., Swaminathan, T. A., Dixon, D., Long, K., Golder, C. J., Vuong, V. A., Banuelos, S., Greenhouse, R., Snyder, M. P., Lipchik, A. M. & Gruber, J. J., Apr 27 2023, In: Journal of Medicinal Chemistry. 66, 8, p. 5774-5801 28 p.

  Research output: Contribution to journal › Article › peer-review

  • histone acetyltransferase type B complex 100%
  • Histone 55%
  • isoalloxazine 13%
  • Growth 11%
  • Enzyme Activity 10%
  1 Scopus citations

• Actionable genomic landscapes from a real-world cohort of urothelial carcinoma patients

  Gerald, T., Margulis, V., Meng, X., Bagrodia, A., Cole, S., Qin, Q., Call, S. G., Mauer, E., Lotan, Y. & Woldu, S. L., Mar 2023, In: Urologic Oncology: Seminars and Original Investigations. 41, 3, p. 148.e17-148.e24

  Research output: Contribution to journal › Article › peer-review

  • Carcinoma 100%
  • Urinary Bladder Neoplasms 82%
  • Microsatellite Instability 53%
  • Neoplasms 48%
  • Tumor Burden 41%
  1 Scopus citations

• Addressing resistance to PD-1/PD-(L)1 pathway inhibition: Considerations for combinatorial clinical trial designs

  Zhang, T., Forde, P. M., Sullivan, R. J., Sharon, E., Barksdale, E., Selig, W., Ebbinghaus, S., Fusaro, G., Gunenc, D., Battle, D., Burns, R., Hurlbert, M. S., Stewart, M. & Atkins, M. B., May 3 2023, In: Journal for ImmunoTherapy of Cancer. 11, 5, e006555.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Clinical Trials 100%
  • Renal Cell Carcinoma 49%
  • Non-Small Cell Lung Carcinoma 45%
  • Melanoma 42%
  • Nonprofit Organizations 38%
  1 Scopus citations

• A narrative review of the evolving landscape of the management of metastatic gastric cancer: the role of targeted therapies

  Delgado-Ramos, G. M., Fitzsimons, J. & Dhanarajan, A., Dec 2023, In: Journal of Gastrointestinal Oncology. 14, 6, p. 2600-2616 17 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Stomach Neoplasms 100%
  • Immunotherapy 46%
  • Therapeutics 18%
  • Drug Therapy 15%
  • Survival 14%

• Antibiotic Prescriptions in Lung Cancer and Melanoma Populations: Differences With Potential Clinical Implications in the Immunotherapy Era

  Gonugunta, A. S., Von Itzstein, M. S., Hsiehchen, D., Le, T., Rashdan, S., Yang, H., Selby, C., Alvarez, C. & Gerber, D. E., Jan 2023, In: Clinical lung cancer. 24, 1, p. 11-17 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Immunotherapy 100%
  • Prescriptions 95%
  • Melanoma 94%
  • Lung Neoplasms 89%
  • Anti-Bacterial Agents 74%
  4 Scopus citations

• Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response

  Chang, H. L., Schwettmann, B., McArthur, H. L. & Chan, I. S., Sep 15 2023, In: Journal of Clinical Investigation. 133, 18, e172156.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Immunoconjugates 100%
  • Breast Neoplasms 47%
  • Recycling 17%
  • Tumor Microenvironment 15%
  • Adaptive Immunity 15%
  2 Scopus citations

• An Updated Report on the Prevalence of Prior Cancer among Persons Newly Diagnosed with Cancer in the Surveillance, Epidemiology, and End Results Program

  Murphy, C. C., Tortolero, G. A., Gerber, D. E. & Pruitt, S. L., Aug 17 2023, In: JAMA Oncology. 9, 8, p. 1147-1150 4 p.

  Research output: Contribution to journal › Article › peer-review
  2 Scopus citations

• A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer

  Page, D. B., Pucilowska, J., Chun, B., Kim, I., Sanchez, K., Moxon, N., Mellinger, S., Wu, Y., Koguchi, Y., Conrad, V., Redmond, W. L., Martel, M., Sun, Z., Campbell, M. B., Conlin, A., Acheson, A., Basho, R., McAndrew, P., El-Masry, M., Park, D., & 8 othersBennetts, L., Seitz, R. S., Nielsen, T. J., McGregor, K., Rajamanickam, V., Bernard, B., Urba, W. J. & McArthur, H. L., Dec 2023, In: npj Breast Cancer. 9, 1, 53.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • pembrolizumab 100%
  • Capecitabine 89%
  • Triple Negative Breast Neoplasms 85%
  • Paclitaxel 71%
  • Biomarkers 37%

• A phase II clinical trial evaluating the safety and efficacy of durvalumab as first line therapy in advanced and metastatic non-small cell lung cancer patients with Eastern Cooperative Oncology Group performance status of 2

  Shaverdashvili, K., Reyes, V., Wang, H., Mehta, D., Marsh, C., Waas, J. K., VanderWeele, R. A., Peracha, S. M., Liang, H., Socinski, M. A., Gerber, D. E., Dowell, J. E. & Villaruz, L. C., Dec 2023, In: EClinicalMedicine. 66, 102317.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • durvalumab 100%
  • Phase II Clinical Trials 70%
  • Non-Small Cell Lung Carcinoma 51%
  • Safety 33%
  • Survival 16%

• Approaches to Continuing COVID-19-Related Clinical Research Practices after the Pandemic - Must Cinderella Leave the Ball?

  Gerber, D. E. & Barksdale, E. K. S., Aug 17 2023, In: JAMA Oncology. 9, 8, p. 1027-1028 2 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access
  2 Scopus citations

• A rare case of advanced metaplastic breast carcinoma with response to treatment with Sacituzumab govitecan

  Dong, S., Fang, Y. & Syed, S., Jun 2023, In: Current Problems in Cancer: Case Reports. 10, 100239.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • sacituzumab govitecan 100%
  • Breast Neoplasms 30%
  • Immunoconjugates 25%
  • Triple Negative Breast Neoplasms 23%
  • atezolizumab 15%

• Assessing Barriers and Facilitators to Lung Cancer Screening: Initial Findings from a Patient Navigation Intervention

  Lee, S. J. C., Lee, J., Zhu, H., Chen, P. M., Wahid, U., Hamann, H. A., Bhalla, S., Cardenas, R. C., Natchimuthu, V. S., Johnson, D. H., Santini, N. O., Patel, H. R. & Gerber, D. E., Jun 1 2023, In: Population Health Management. 26, 3, p. 177-184 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Patient Navigation 100%
  • Early Detection of Cancer 62%
  • Lung Neoplasms 52%
  • telephone 30%
  • Underinsured 26%

• AXL Inhibitors: Status of Clinical Development

  Bhalla, S. & Gerber, D. E., May 2023, In: Current oncology reports. 25, 5, p. 521-529 9 p.

  Research output: Contribution to journal › Review article › peer-review

  • Neoplasms 100%
  • Hematologic Neoplasms 78%
  • Growth 78%
  • Therapeutics 76%
  • Drug Resistance 70%
  9 Scopus citations

• Cancer Clinical Trials beyond Pandemic: Report of an American Statistical Association Biopharmaceutical Section Open Forum Discussion

  Sridhara, R., Barksdale, E., Marchenko, O., Jiang, Q., Ando, Y., Bloomquist, E., Coory, M., Crouse, M., Degtyarev, E., Framke, T., Freidlin, B., Gerber, D. E., Gwise, T., Josephson, F., Hess, L., Kluetz, P., Li, D., Mandrekar, S., Posch, M., Rantell, K., & 12 othersRatitch, B., Raven, A., Roes, K., Rufibach, K., Sarac, S. B., Simon, R., Singh, H., Theoret, M., Thomson, A., Zuber, E., Shen, Y. L. & Pazdur, R., 2023, In: Statistics in Biopharmaceutical Research. 15, 2, p. 444-449 6 p.

  Research output: Contribution to journal › Letter › peer-review

  • Oncology 100%
  • Pandemics 76%
  • Pharmaceutical Industry 74%
  • Cancer 73%
  • Biological Products 70%

• Cell Competition Shapes Metastatic Latency and Relapse

  Kim, K., Huang, H., Parida, P. K., He, L., Marquez-Palencia, M., Reese, T. C., Kapur, P., Brugarolas, J., Brekken, R. A. & Malladi, S., Jan 9 2023, In: Cancer discovery. 13, 1, p. 85-97 13 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Cell Shape 100%
  • Recurrence 48%
  • Kidney Neoplasms 17%
  • Neoplasms 14%
  • Cysteine 14%
  6 Scopus citations

• Characteristics and clinical outcomes in young-onset cholangiocarcinoma

  Reddy, S., Goksu, S. Y., Sanford, N. N., Kainthla, R., Hsiehchen, D., Sanjeevaiah, A., Jones, A. L., Karagkounis, G., Al Mutar, S., Ahn, C., Beg, M. S. & Kazmi, S. M., Jul 2023, In: Cancer Medicine. 12, 13, p. 14094-14103 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Cholangiocarcinoma 100%
  • Comorbidity 12%
  • Drug Therapy 9%
  • Neoplasms 7%
  • Radiation 5%
  2 Scopus citations

• Comparison of methods for texture analysis of H-scan ultrasound images from breast cancer patients undergoing neoadjuvant chemotherapy

  Dolui, S., Torkzaban, M., Dogan, B., James, D., Wessner, C., Porembka, J., MacHado, P., Ozcan, B., Unni, N., Khalaf, M. A., Forsberg, F., Nam, K. & Hoyt, K., 2023, IUS 2023 - IEEE International Ultrasonics Symposium, Proceedings. IEEE Computer Society, (IEEE International Ultrasonics Symposium, IUS).

  Research output: Chapter in Book/Report/Conference proceeding › Conference contribution

  • chemotherapy 100%
  • breast 72%
  • cancer 64%
  • textures 57%
  • tumors 32%

• Decentralized Clinical Trials in Oncology: Are We Ready for a Virtual-First Paradigm?

  Fu, S., Gerber, D. E. & Beg, M. S., Jan 10 2023, In: Journal of Clinical Oncology. 41, 2, p. 181-185 5 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access
  10 Scopus citations

• Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses

  Kumar, A., Ramani, V., Bharti, V., De Lima Bellan, D., Saleh, N., Uzhachenko, R., Shen, C., Arteaga, C., Richmond, A., Reddy, S. M. & Vilgelm, A., May 25 2023, In: Journal for ImmunoTherapy of Cancer. 11, 5

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Cyclin-Dependent Kinase 6 100%
  • Cyclin-Dependent Kinase 4 83%
  • Cell- and Tissue-Based Therapy 61%
  • Dendritic Cells 58%
  • Immunity 53%
  1 Scopus citations

• Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance

  Lyu, J., Liu, Y., Gong, L., Chen, M., Madanat, Y. F., Zhang, Y., Cai, F., Gu, Z., Cao, H., Kaphle, P., Kim, Y. J., Kalkan, F. N., Stephens, H., Dickerson, K. E., Ni, M., Chen, W., Patel, P., Mims, A. S., Borate, U., Burd, A., & 8 othersCai, S. F., Yin, C. C., You, M. J., Chung, S. S., Collins, R. H., DeBerardinis, R. J., Liu, X. & Xu, J., Jan 9 2023, In: Cancer discovery. 13, 1, p. 170-193 24 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Mutation 100%
  • Acute Myeloid Leukemia 73%
  • NADP 55%
  • Leukemia 41%
  • Amino Acids 35%
  5 Scopus citations

• Disease Etiology and Outcomes After Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma: Post-Hoc Analysis of IMbrave150

  Espinoza, M., Muquith, M., Lim, M., Zhu, H., Singal, A. G. & Hsiehchen, D., Jul 2023, In: Gastroenterology. 165, 1, p. 286-288.e4

  Research output: Contribution to journal › Short survey › peer-review
  16 Scopus citations

• Distinct mutational and clinicopathologic profiles characterize acute myeloid leukemia with cup-like nuclei

  Oertling, E., Fuda, F., Koduru, P., Chen, M., Weinberg, O., Juntilla, M., Jaso, J., Vusirikala, M., Chung, S., Geethakumari, P. R., Madanat, Y. F., Collins, R., Gagan, J. & Chen, W., Jan 2023, In: Leukemia Research. 124, 106995.

  Research output: Contribution to journal › Letter › peer-review

• Effect of concurrent beta-blocker use in patients receiving immune checkpoint inhibitors for advanced solid tumors

  Mellgard, G., Patel, V. G., Zhong, X., Joshi, H., Qin, Q., Wang, B., Parikh, A., Jun, T., Alerasool, P., Garcia, P., Gogerly-Moragoda, M., Leiter, A., Gallagher, E. J., Oh, W. K., Galsky, M. D. & Tsao, C. K., Jul 2023, In: Journal of Cancer Research and Clinical Oncology. 149, 7, p. 2833-2841 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Survival 100%
  • Adrenergic Agents 70%
  • Neoplasms 69%
  • Carcinoma 47%
  • Duration of Therapy 33%
  4 Scopus citations